COIOSDeep risk insights through multi-disciplinary research across the globe
people walking on street during daytime
Item new Peer-reviewed Added

Oral orforglipron is tested for cardiovascular safety against insulin in type 2 diabetes

A phase 3 trial randomised 2749 adults with type 2 diabetes and heart or kidney disease to oral orforglipron or insulin glargine, and followed them for a median two years.

The trial compared oral orforglipron with insulin glargine in 2749 adults with type 2 diabetes at increased cardiovascular risk. 86% had established cardiovascular disease and 38% chronic kidney disease at entry. The outcome counted was cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or admission for unstable angina, with non-inferiority set at a hazard ratio below 1.8.

Why it is interesting: First cardiovascular safety evidence for an oral, non-peptide GLP-1 drug, set against an active comparator.

Source
The Lancet, 30 September 2026
Paper
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
Authors
Klein KR, Wysham C, Tuttle KR, Davies MJ, Cox D, Chen J et al.
DOI
10.1016/s0140-6736(26)01865-9
Type
Peer-reviewed article
Design
Phase 3 event-driven randomised open-label active-comparator non-inferiority trial, 2749 adults, 317 sites in 16 countries, median follow-up 2 years, 2023-2024
Verdict
New finding
Driver
Innovation in treatment
Driver
Heart and stroke
Driver
Obesity, diabetes and GLP-1
Notice
Corrected 17 October 2026 (notice)
Attention
2 citations (Crossref) · as of 2026-11-20

Other drivers in Tomorrow's world